Novo Nordisk Gets CDSCO Panel conditional nod to study Insulin icodec
New Delhi: The drug major Novo Nordisk has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the phase III b clinical study of the Insulin icodec, an investigational ultralong-acting basal insulin analogue.
However, this approval is subject to the condition that the firm should submit the addendum, clearly defining rescue and withdrawal criteria.
This came after the drug maker Novo Nordisk presented Phase 3b clinical study protocol no. NN1436-7724.
Insulin icodec is an ultra-long-acting basal insulin analogue developed by Novo Nordisk. It is currently undergoing Phase 3 trials.
It is given as a weekly subcutaneous injection to help control blood sugar levels in people with diabetes. With a duration of action of over 8 days (compared to 42 hours for insulin degludec, the previous longest-acting insulin analogue), it becomes a once-weekly basal insulin. This substance is composed of two peptide chains, disulfide bridges. In addition, the 21 amino acid residue chain has two internal disulfide bridges and the second chain is 29 residues long.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.